Sugi Predict

Sugi Predict / Compounds / SCHEMBL4484073

SCHEMBL4484073

SCHEMBL4484073

O=C(CCc1ccc(Br)cc1)CCc1ccc(Br)cc1

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 2/20 0.53
▸ FFAR4 Q5NUL3 1/20 0.53
▸ PDPK1 O15530 1/20 0.51
▸ TAAR1 Q96RJ0 3/20 0.50
▸ HTR2A P28223 1/20 0.50
▸ POLB P06746 1/20 0.47
▸ CTDSP1 Q9GZU7 1/20 0.47
▸ F2RL1 P55085 1/20 0.47
▸ MMP12 P39900 1/20 0.46
▸ IDO1 P14902 1/20 0.45
▸ BCHE P06276 1/20 0.44
▸ ACHE P22303 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27881428 0.98 FFAR1 (0.51) FFAR1FFAR4PDPK1TAAR1HTR2A
SCHEMBL9680739 0.94 MMP12 (0.55) FFAR1FFAR4PDPK1TAAR1HTR2A
SCHEMBL12144575 0.92 FFAR1 (0.59) FFAR1FFAR4PDPK1POLBMMP12
SCHEMBL13286340 0.90 TDP1 (0.59) FFAR1FFAR4POLB
SCHEMBL11217816 0.90 CNR1 (0.54) FFAR1FFAR4POLB
SCHEMBL25907921 0.90 FFAR1 (0.46) FFAR1FFAR4PDPK1TAAR1HTR2A
SCHEMBL9709577 0.90 IAPP (0.59) FFAR1FFAR4PDPK1TAAR1POLB
SCHEMBL28570070 0.89 FFAR1 (0.49) FFAR1FFAR4PDPK1TAAR1HTR2A
SCHEMBL410494 0.89 FFAR1 (0.49) FFAR1FFAR4PDPK1TAAR1HTR2A
SCHEMBL9681011 0.88 HDAC1 (0.48) FFAR1FFAR4PDPK1TAAR1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113845442-B Method for preparing p-bromobenzonitrile 孙国伟 2023-09-29 — — CN disclosed
CN-116462712-A Compound, organic electroluminescent device and electronic equipment 华为技术有限公司 2023-07-21 — — CN disclosed
WO-2023134696-A1 COMPOUND, ORGANIC LIGHT EMITTING DEVICE, AND ELECTRONIC DEVICE 华为技术有限公司 2023-07-20 — — WO disclosed
CN-103946220-B Inhibitors of baculovirus containing fragment {2- [4- (biphenyl-4-yl) -1H-imidazol-2-yl ] pyrrolidine-1-carbonylmethyl } amine 施万生物制药研发IP有限责任公司 2017-12-22 — — CN disclosed
CN-103304551-B Hepatitis AG14361 北京凯因科技股份有限公司 2017-06-13 — — CN disclosed
CN-103288721-B (4-(4-[6-(trifluoromethylpyridin-3-base amino)-containing N heteroaryl]-phenyl)-cyclohexyl)-acetogenin and pharmaceutical use thereof NOVARTIS AG (CH) 2016-04-20 — — CN disclosed
US-9006503-B2 Organic electroluminescence devices containing substituted benzo[C]phenanthrenes MERCK PATENT GMBH (DE) 2015-04-14 — — US disclosed
US-9006503-B2 Organic electroluminescence devices containing substituted benzo[C]phenanthrenes MERCK PATENT GMBH (DE) 2015-04-14 — — US disclosed
CN-102863428-B Spiro-compounds taken as hepatitis c virus (HCV) inhibitor GUANGDONG HEC PHARMACEUTICAL 2014-12-24 — — CN disclosed
CN-103946220-A Inhibitors of baculovirus containing fragment {2- [4- (biphenyl-4-yl) -1H-imidazol-2-yl ] pyrrolidine-1-carbonylmethyl } amine THERAVANCE INC 2014-07-23 — — CN disclosed
EP-1487841-A1 THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS Abbott Laboratories (US) 2004-12-22 — — EP disclosed
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBVIE INC. 2004-01-22 — — US disclosed
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-12-04 — — US disclosed
WO-2003080625-A1 THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2003-10-02 — — WO disclosed
US-20030181468-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-09-25 — — US disclosed
EP-0771196-B1 EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS LILLY CO ELI (US) 1999-12-08 — — EP disclosed
US-5717109-A CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS ELI LILLY AND COMPANY (US) 1998-02-10 — — US disclosed
US-5136013-A Polyesters BAYER AKTIENGESELLSCHAFT (DE) 1992-08-04 — — US disclosed
US-5068300-A BIFUNCTIONAL STILBENE COMPOUNDS CONTAINING AT LEAST ONE Z-CONFIGURATED STILBENE GROUP, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE PREPARATION OF POLYMERS BAYER AKTIENGESELLSCHAFT (DE) 1991-11-26 — — US disclosed
US-4340756-A Polyamine compounds as antibacterial agents MERCK & CO., INC. (US) 1982-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK FFAR1 3709/4885FFAR4 4157/4885PDPK1 144/4885
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK FFAR1 3709/4885FFAR4 4157/4885PDPK1 144/4885
US-20030181468-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK FFAR1 3664/4885FFAR4 4103/4885PDPK1 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.